Nearly Half of All New Brand Name Drugs Cost More Than $150,000 Per Year In case you missed it, a new academic study published in The Journal of the American Medical Association (JAMA) from researchers affiliated with Harvard University and Brigham and Women’s Hospital showcases how Big Pharma increasingly engages in egregious pricing practices on […]
Scoring Shows Solutions to Crack Down on Branded Drug Companies’ Anti-Competitive Tactics Would Save Consumers Billions and Bring More Affordable Alternatives to Market In case you missed it, on Tuesday the Congressional Budget Office (CBO) released new scores that found three patent reform bills targeting Big Pharma’s anti-competitive behavior would deliver significant savings for taxpayers […]
Brand Name Drug Companies Posted Massive Profit Growth and Invested Heavily in Share Buybacks and Dividends Two recent reports from Evaluate Vantage and Endpoints News detail the banner year Big Pharma had in 2021, while the industry continued to raise prescription drug prices amid the COVID-19 pandemic. The reports show that Big Pharma invested heavily […]
Brand Name Drug Companies Four Times as Likely to Reformulate Blockbuster Products to Extend Market Exclusivity In case you missed it, a recent study published in JAMA Health Forum examines Big Pharma company applications for new formulations for prescription drugs approved by the U.S. Food and Drug Administration (FDA) from 1996 to 2010. New formulations […]
Brand Name Drug Companies Prevent Competition from More Affordable Alternatives by Gaming the Patent System and Deploying Tactics Like Product Hopping In case you missed it, STAT News covered a new academic analysis published in Health Affairs that found manufacturers of brand name inhalers used to treat asthma and chronic obstructive pulmonary disease engage in […]
Part D Spending on 10 Most Popular Medications Over Five Years Averages Five Times What Drug Companies Claim to Invest in R&D In case you missed it, AARP’s Public Policy Institute released a new analysis Wednesday examining Medicare Part D spending over a five year period, from 2016 to 2020, on the 10 top-selling brand name […]
Another Round of Big Pharma Giants Beat Wall Street Expectations In Q1 After Hiking Prices Throughout Pandemic Big Pharma giants Bristol-Myers Squibb, Pfizer, AbbVie and AstraZeneca all held earnings calls within the past week that beat Wall Street analysts’ expectations. The brand name drug companies’ strong earnings came after the companies launched several rounds of […]
Lawmakers Should Focus Attention on Brand Name Drug Companies’ Egregious Practices, Recommit to Market-Based Solutions to Lower Drug Prices On Thursday, May 5, the U.S. Senate Committee on Commerce, Science and Transportation’s Subcommittee on Consumer Protection, Product Safety, and Data Security is set to hold a hearing on “Ensuring Fairness and Transparency in the Market […]
Big Pharma Giants Repeatedly Hike Prices and Continue to Beat Wall Street Expectations This week, Novartis, GlaxoSmithKline, Amgen, and Roche all reported earnings for the first quarter. All four Big Pharma giants engaged in price hikes during the COVID-19 pandemic and have a history of engaging in anti-competitive tactics to undermine competition and drive-up prices. […]
Patients for Affordable Drugs Now Poll Finds Vast Majority of Voters Reject Pharmaceutical Industry Rhetoric, Want Lawmakers to Hold Big Pharma Accountable A new national survey from Patients for Affordable Drugs Now shows the vast majority of American voters continue to support solutions to lower prescription drug prices by holding Big Pharma accountable. The survey […]